At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
Ramucirumab +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Ramucirumab, Placebo, and 3 other interventions for Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Completed, enrolled 191 participants across 34 sites in 3 countries.
Detailed Summary
The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionOct 2017
Study CompletionMar 2021
TodayJul 2026
First PostedSep 2, 2015
Enrollment StartOct 5, 2015
Primary CompletionOct 25, 2017
Study CompletionMar 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.8 years ago
Interventions
Ramucirumabdrug
Administered IV
Placebodrug
Administered IV
S-1drug
Administered PO
Oxaliplatindrug
Administered IV
Paclitaxeldrug
Administered IV